New Anesthesia Technique Helps Show Cause of Obstruction in Sleep Apnea
Article ID: 621214
Released: 29-Jul-2014 9:00 AM EDT
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Newswise — July 29, 2014 – A simplified anesthesia procedure may enable more widespread use of preoperative testing to demonstrate the cause of airway obstruction in patients with severe sleep apnea, suggests a study in Anesthesia & Analgesia.
Dr. Joshua H. Atkins and Dr. Jeff E. Mandel of the University of Pennsylvania and their colleagues have developed a new "ramp control" anesthetic technique for putting patients to sleep briefly-just enough to show the "obstructive anatomy" responsible for sleep apnea. The simplified technique requires no special expertise and limits drops in blood oxygen level during testing.
Simplified Approach to Testing Before Apnea Surgery
The researchers evaluated their anesthetic technique in 97 patients participating in a study of robot-assisted surgery for severe sleep apnea. Visualizing the site of the obstruction in the upper airway is an important part of planning for apnea surgery. This can be done using a procedure called "drug-induced sleep endoscopy" (DISE), in which stepwise doses of anesthetic doses are given to put the patient to sleep and reproduce the airway obstruction causing apnea.
However, it's challenging to achieve just the right anesthetic dosage—enough to cause typical sleep-related obstruction without causing prolonged unconsciousness or causing a deep drop in blood oxygen level (oxygen saturation). The standard technique for DISE is time-consuming and not well-suited for widespread clinical use.
In the new ramp control approach, a computerized algorithm is used to calculate the two-dose sequence of anesthetic administration likely to produce sedation in each individual patient. By contrast, the standard stepwise approach to DISE uses a sequence of up to nine doses.
The 97 patients studied had severe sleep apnea, with a median of 48 apnea-hypopnea events (complete or partial interruptions of breathing) per hour on standard testing in the sleep laboratory. The patients were being evaluated for surgery after receiving no benefit from continuous positive airway pressure (CPAP), the standard treatment for sleep apnea.
The ramp-control DISE approach allowed doctors to see and photograph the obstructive anatomy in all 97 patients. The median time to put the patient to sleep and demonstrate the cause of obstruction was just under four minutes.
Just as important, the necessary level of sedation was achieved without an undue drop in oxygen saturation levels. The median lowest oxygen saturation level during DISE was about 91 percent, compared to an 81 percent value recorded in standard sleep studies. (Normal oxygen saturation is between 95 and 100 percent.)
Two-Dose Technique May Promote Wider Use of DISE
Although it's not new, DISE is still considered a "niche procedure"—not commonly performed by most anesthesiologists. It's easy to "overshoot" the anesthetic dose; this may lead to drops in oxygen saturation, requiring airway support steps to maintain the patient's blood oxygen level. Dr Atkins and colleagues note that their study included a "challenging" population of obese patients with severe sleep apnea, who have often been excluded from studies of other anesthetic techniques for sleep apnea.
The ramp-control DISE technique is efficient, administering just enough anesthetic to produce the desired level of sedation within a few minutes; and safe, with relatively small drops in blood oxygen saturation level. "The effective sedation seen in this study with a low rate of desaturation and infrequent need for airway support is an important result," Dr Atkins and coauthors write.
By simplifying the steps to anesthesia administration, the researchers believe their simplified approach will help to make DISE more widely available for evaluation of patients being considered for sleep apnea surgery. However, more research will be needed to determine how well the new technique can be generalized to everyday clinical practice at busy surgical centers.
About Anesthesia & Analgesia
Anesthesia & Analgesia was founded in 1922 and was issued bi-monthly until 1980, when it became a monthly publication. A&A is the leading journal for anesthesia clinicians and researchers and includes more than 500 articles annually in all areas related to anesthesia and analgesia, such as cardiovascular anesthesiology, patient safety, anesthetic pharmacology, and pain management. The journal is published on behalf of the IARS by Lippincott Williams & Wilkins (LWW), a division of Wolters Kluwer Health.
About the IARS
The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia related practice; sponsors the SmartTots initiative in partnership with the FDA; and publishes the monthly journal Anesthesia & Analgesia in print and online.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries worldwide, clinicians rely on Wolters Kluwer Health’s market leading information-enabled tools and software solutions throughout their professional careers from training to research to practice. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2013 annual revenues of €3.6 billion ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.